Manufacturers announce resubmission of biologics license application to FDA for plasminogen (Ryplazim) for congenital plasminogen deficiency

Resubmission is based on a phase 2/3 trial in 15 patients which found that all patients treated with plasminogen achieved at least the targeted increase from baseline in their individual trough plasminogen activity levels through 12 weeks of therapy.


Biospace Inc.